Scholar Rock Holding Corp SRRK
We take great care to ensure that the data presented and summarized in this overview for Scholar Rock Holding Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SRRK
View all-
Price T Rowe Associates Inc Baltimore, MD9.28MShares$297 Million0.05% of portfolio
-
Siren, L.L.C. New York, NY9.25MShares$296 Million17.66% of portfolio
-
Black Rock Inc. New York, NY5.66MShares$181 Million0.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA5.61MShares$179 Million74.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.74MShares$152 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.55MShares$145 Million15.38% of portfolio
-
Marshall Wace, LLP London, X02.95MShares$94.1 Million0.16% of portfolio
-
Polar Capital Holdings PLC London, X02.71MShares$86.5 Million0.72% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.66MShares$85 Million2.2% of portfolio
-
State Street Corp Boston, MA2.64MShares$84.3 Million0.0% of portfolio
Latest Institutional Activity in SRRK
Top Purchases
Top Sells
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SRRK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 27
2025
|
Keith Woods Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
600,000
+47.73%
|
-
|
|
Apr 27
2025
|
Vikas Sinha Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
600,000
+47.73%
|
-
|
|
Apr 27
2025
|
David Hallal CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,500,000
+36.01%
|
-
|
|
Apr 27
2025
|
Akshay Vaishnaw President of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
600,000
+44.69%
|
-
|
|
Apr 25
2025
|
Tracey Sacco Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.26%
|
$165,000
$33.15 P/Share
|
|
Apr 25
2025
|
Tracey Sacco Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.15%
|
$50,000
$10.0 P/Share
|
|
Mar 24
2025
|
Erin Moore Interim PFO and PAO |
SELL
Open market or private sale
|
Direct |
13,564
-14.1%
|
$447,612
$33.12 P/Share
|
|
Mar 24
2025
|
Erin Moore Interim PFO and PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,564
+6.79%
|
$244,152
$18.69 P/Share
|
|
Mar 24
2025
|
Tracey Sacco Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,500
-4.22%
|
$214,500
$33.3 P/Share
|
|
Mar 24
2025
|
Tracey Sacco Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.01%
|
$50,000
$10.0 P/Share
|
|
Mar 17
2025
|
Katie Peng |
SELL
Open market or private sale
|
Direct |
1,006
-3.21%
|
$34,204
$34.42 P/Share
|
|
Mar 10
2025
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
142,292
-32.7%
|
$4,980,220
$35.34 P/Share
|
|
Mar 10
2025
|
Edward H Myles COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
112,897
+9.53%
|
$1,354,764
$12.5 P/Share
|
|
Mar 10
2025
|
Tracey Sacco Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,855
+27.55%
|
-
|
|
Mar 10
2025
|
Junlin Ho GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
32,145
+12.68%
|
-
|
|
Mar 10
2025
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
113,570
+21.07%
|
-
|
|
Mar 10
2025
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
34,285
+25.25%
|
-
|
|
Mar 10
2025
|
Caryn Parlavecchio CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
23,570
+12.58%
|
-
|
|
Mar 10
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
32,145
+18.33%
|
-
|
|
Feb 19
2025
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
68,510
-14.54%
|
$2,534,870
$37.5 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.68M shares |
|---|---|
| Bona fide gift | 37.5K shares |
| Other acquisition or disposition | 112K shares |
| Exercise of conversion of derivative security | 372K shares |
| Bona fide gift | 37.5K shares |
|---|---|
| Open market or private sale | 3.95M shares |
| Other acquisition or disposition | 599K shares |
| Exercise of conversion of derivative security | 206K shares |